中文摘要：

目的 探讨miR-17-92在难治性急性淋巴细胞白血病（RALL）患者外周血淋巴细胞中的表达情况.方法 用淋巴细胞分离液提取21例经2个疗程以上标准方案化疗未获缓解的RALL患者和15例体内敏感急性淋巴细胞白血病（ALL）患者外周血淋巴细胞,应用MTT法检测该36例白血病患者淋巴细胞对多柔比星和顺铂的敏感性,从体外实验结果与临床疗效相符患者的淋巴细胞中提取总RNA,应用实时荧光定量PCR法检测样品中miR-17-92的表达情况.结果 MTT法细胞敏感性实验表明,18例RALL患者淋巴瘤细胞抑制率（IR）＜30％,为不敏感或耐药,14例体内敏感ALL患者IR＞30％,为中度敏感或敏感；将此32例患者纳入本次研究对象.实时荧光定量PCR检测显示,与对化疗药物敏感ALL患者组相比,RALL患者淋巴细胞中miR-17-92相对表达量升高（7.12±1.03比3.21±0.63,P＜0.05）.结论 miR-17-92在RALL患者淋巴细胞中的表达水平相对较高,这可能与RALL多药耐药的发生、发展相关.

英文摘要：

Objective To investigate the expression levels of miR-17-92 in peripheral blood lymphocytes of patients with refractory acute lymphocytic leukemia（RALL）.Methods Peripheral blood lymphocytes of 21 RALL patients and 15 chemotherapy-sensitive ALL patients in vivo were isolated respectively.MTT assay was carried out to evaluate the sensitivity of lymphocytes to adriamycin （ADM）and cisplatin（DDP）in patients.Total RNA was extracted from lymphocytes of blood samples from 32 patients.The real-time PCR method was performed to detect the expression levels of miR-17-92.Results The MTT assay results showed that the inhibition rates（IR）in 18 RALL patients were less than 30％,which were sensitive or drug resistant,and the IR in 14 chemotherapy-sensitive ALL patients were higher than 30％,which were chemotherapy-sensitive.The relative expression levels of miR-17-92 in lymphocytes of RALL patients and chemotherapy-sensitive ALL patients were 7.12±1.03 and 3.21±0.63 respectively,which showed that compared with the chemotherapy-sensitive ALL patients,the relative expression of miR-17-92 in lymphocytes of RALL patients was significantly increased（P＜0.05）.Conclusions The expression level of miR-17-92 in lymphocytes of RALL patients is up-regulated,miR-17-92 may have relationship with the occurrence and development of multi-drug resistance in RALL.